130 related articles for article (PubMed ID: 15859929)
1. Ten-year follow-up of recipients of a kidney or heart transplant who received induction therapy with a monoclonal antibody against the interleukin-2 receptor.
Wabbijn M; Balk AH; van Domburg RT; Vantrimpont PJ; van Riemsdijk IC; Baan CC; Weimar W; van Gelder T
Exp Clin Transplant; 2004 Jun; 2(1):201-7. PubMed ID: 15859929
[TBL] [Abstract][Full Text] [Related]
2. A randomized, placebo-controlled trial with anti-interleukin-2 receptor antibody for immunosuppressive induction therapy after liver transplantation.
Langrehr JM; Glanemann M; Guckelberger O; Klupp J; Neumann U; Machens C; Lohmann R; Knoop M; Lobeck H; Schlag H; Keck H; Settmacher U; Bechstein WO; Neuhaus PJ
Clin Transplant; 1998 Aug; 12(4):303-12. PubMed ID: 9686324
[TBL] [Abstract][Full Text] [Related]
3. Ten-year follow-up of a prospective, randomized trial of BT563/bb10 versus anti-thymocyte globulin as induction therapy after heart transplantation.
Bonaros N; Dunkler D; Kocher A; Imhof M; Grimm M; Zuckermann A; Wolner E; Laufer G
J Heart Lung Transplant; 2006 Sep; 25(9):1154-63. PubMed ID: 16962480
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up after induction treatment with monoclonal anti-interleukin-2 receptor antibody (BT563) in kidney allograft recipients: a double-blind, placebo-controlled trial.
van Gelder T; Zietse R; Yzermans JN; Rischen-Vos J; Vaessen LM; Weimar W
Transplant Proc; 1996 Dec; 28(6):3221-2. PubMed ID: 8962247
[No Abstract] [Full Text] [Related]
5. Long-term results (10 years) of a prospective trial comparing Lo-tact-1 monoclonal antibody and anti-thymocyte globulin induction therapy in kidney transplantation.
Beaudreuil S; Durrbach A; Noury J; Ducot B; Kriaa F; Bazin H; Charpentier B
Transpl Int; 2006 Oct; 19(10):814-20. PubMed ID: 16961773
[TBL] [Abstract][Full Text] [Related]
6. Intragraft monitoring of rejection after prophylactic treatment with monoclonal anti-interleukin-2 receptor antibody (BT563) in heart transplant recipients.
van Gelder T; Mulder AH; Balk AH; Mochtar B; Hesse CJ; Baan CC; Vaessen LM; Weimar W
J Heart Lung Transplant; 1995; 14(2):346-50. PubMed ID: 7779855
[TBL] [Abstract][Full Text] [Related]
7. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy.
Woodle ES; First MR; Pirsch J; Shihab F; Gaber AO; Van Veldhuisen P;
Ann Surg; 2008 Oct; 248(4):564-77. PubMed ID: 18936569
[TBL] [Abstract][Full Text] [Related]
8. 20-year follow-up results of a randomized controlled trial comparing antilymphocyte globulin induction to no induction in renal transplant patients.
Cantarovich M; Durrbach A; Hiesse C; Ladouceur M; Benoit G; Charpentier B
Transplantation; 2008 Dec; 86(12):1732-7. PubMed ID: 19104413
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial comparing safety and efficacy of OKT3 and a monoclonal anti-interleukin-2 receptor antibody (BT563) in the prevention of acute rejection after heart transplantation.
van Gelder T; Balk AH; Jonkman FA; Zietse R; Zondervan P; Hesse CJ; Vaessen LM; Mochtar B; Weimar W
Transplantation; 1996 Jul; 62(1):51-5. PubMed ID: 8693545
[TBL] [Abstract][Full Text] [Related]
10. The Bergamo Kidney Transplant Program.
Perico N; Cravedi P; Ruggenenti P; Gotti E; Rota G; Locatelli G; Gambara V; Perna A; Rota S; Remuzzi G
Clin Transpl; 2005; ():85-100. PubMed ID: 17424727
[TBL] [Abstract][Full Text] [Related]
11. Long-term analysis of combined liver and kidney transplantation at a single center.
Ruiz R; Kunitake H; Wilkinson AH; Danovitch GM; Farmer DG; Ghobrial RM; Yersiz H; Hiatt JR; Busuttil RW
Arch Surg; 2006 Aug; 141(8):735-41; discussion 741-2. PubMed ID: 16924080
[TBL] [Abstract][Full Text] [Related]
12. Survival, graft atherosclerosis, and rejection incidence in heart transplant recipients treated with statins: 5-year follow-up.
Stojanovic I; Vrtovec B; Radovancevic B; Radovancevic R; Yazdanbakhsh AP; Thomas CD; Frazier OH
J Heart Lung Transplant; 2005 Sep; 24(9):1235-8. PubMed ID: 16143239
[TBL] [Abstract][Full Text] [Related]
13. A prospective randomized controlled study on the efficacy and tolerance of two antilymphocytic globulins in the prevention of rejection in first-heart transplant recipients.
Schnetzler B; Leger P; Völp A; Dorent R; Pavie A; Gandjbakhch I
Transpl Int; 2002 Jun; 15(6):317-25. PubMed ID: 12072903
[TBL] [Abstract][Full Text] [Related]
14. Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients.
Kobashigawa JA; Moriguchi JD; Laks H; Wener L; Hage A; Hamilton MA; Cogert G; Marquez A; Vassilakis ME; Patel J; Yeatman L
J Heart Lung Transplant; 2005 Nov; 24(11):1736-40. PubMed ID: 16297773
[TBL] [Abstract][Full Text] [Related]
15. The impact of induction on survival after lung transplantation: an analysis of the International Society for Heart and Lung Transplantation Registry.
Hachem RR; Edwards LB; Yusen RD; Chakinala MM; Alexander Patterson G; Trulock EP
Clin Transplant; 2008; 22(5):603-8. PubMed ID: 18435784
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcomes of kidney transplantation in recipients 60 years of age and older at the University of Florida.
Foley DP; Patton PR; Meier-Kriesche HU; Li Q; Shenkman B; Fujita S; Reed A; Hemming AW; Kim RD; Howard RJ
Clin Transpl; 2005; ():101-9. PubMed ID: 17424728
[TBL] [Abstract][Full Text] [Related]
17. ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a single center experience.
Donauer J; Wilpert J; Geyer M; Schwertfeger E; Kirste G; Drognitz O; Walz G; Pisarski P
Xenotransplantation; 2006 Mar; 13(2):108-10. PubMed ID: 16623802
[TBL] [Abstract][Full Text] [Related]
18. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials.
Webster AC; Playford EG; Higgins G; Chapman JR; Craig JC
Transplantation; 2004 Jan; 77(2):166-76. PubMed ID: 14742976
[TBL] [Abstract][Full Text] [Related]
19. Preoperative single-bolus high-dose antithymocyte globulin as induction therapy in sensitized renal transplant recipients.
Wang D; Wu WZ; Yang SL; Chen JH; Tan JM
Chin Med J (Engl); 2006 Oct; 119(20):1683-8. PubMed ID: 17097014
[TBL] [Abstract][Full Text] [Related]
20. Daclizumab is associated with decreased rejection and improved patient survival in renal transplant recipients.
Morris JA; Hanson JE; Steffen BJ; Chu AH; Chi-Burris KS; Gotz VP; Gordon RD
Clin Transplant; 2005 Jun; 19(3):340-5. PubMed ID: 15877795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
